Comparison of Cerb B2 expression and Ki-67 index with modifid scarff-bloom-richardson grading system in invasive ductal carcinoma

Aim: Breast cancer is the most frequent cancer among women. Cerb B2 is an oncogene that encodes a transmembrane glycoproteinknown as HER-2 protein or receptor. Ki-67 is nuclear protein associated with cellular proliferation. In this study, we investigatedthe relationships between the histopathologic parameters in the “Modifid Scarff-Bloom-Richardson” microscopic grading andexpression of Cerb B2 and Ki-67 index gene in cases with invasive ductal carcinoma. Breast cancer is the most common type ofcancer in women, but also the second most common cause of death after lung cancer.Material and Methods: In this study examined 45 patients who were diagnosed with invasive ductal carcinoma between January2017 and January 2019 in Sivas Cumhuriyet University, department of surgical oncology. Cases, Cerb B2 expression and Ki-67 indexwere retrospectively screened from pathology recordsResults: Increased expression of Cerb B2 was statistically signifiant related with increased tubule formation, pleomorfim, mitosisrate, and histological grade (p=0.006, p=0.027, p

PDF

___

1. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cacer J Clin 2020;70:7-30.
2. Erkinüresin T. Yaygın insitu duktal karsinomlu invaziv duktal karsinomlar ile insitu duktal karsinomsuz invaziv duktal karsinomların normal meme epitelinde östrojen reseptör ekspresyonunun karşılaştırılması (Uzmanlık Tezi) İstanbul: Haydarpaşa Numune Eğitim ve Araştırma Hastanesi 2009
3. Meyer JS, Alvarez C, Milikowski C, et al. Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index. Mod Pathol 2005;8:1067-78.
4. Rakha EA, Reis-Filho JS, Baehner F, et al. Breast cancer prognostic classifiation in the molecular era: the role of histological grade. Breast Ca Res 2010;12:207.
5. Daglar G, Yuksek YN, Gozalan AU, et al. The prognostic value of histological grade in the outcome of patients with invasive breast cancer. Turk J Med Sci 2010; 40:7-15.
6. Yosef Yarden. Biology of HER2 and its importance in breast cancer, Oncology 2001;61:1-13.
7. Pauletti G, Godolphin W, Slamon DJ et al. detection and quantitation of HER- 2/neu gene amplifiation in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996; 13:63-72.
8. Bundred N.J. Prognostic and Predictive Factors in Breast cancer. Ca Treat Revi 2001;27:137-42.
9. Jansen RLH. Prognostic and predictive factors in breast cancer. Netherlands J of Med 1997;51:65-77.
10. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Ca 1983; 31:13-20
11. Kaya Z. Meme kanserinde matriks metalloproteinaz 1 ve 2 ekspresyonunun diğer prognostik faktörlerle ilişkisi (Uzmanlık Tezi) İstanbul: Okmeydanı Eğitim ve Araştırma Hastanesi 2008.
12. Kontzoglou K, Palla V, Karaolanis G, et al. Others Correlation between Ki67 and breast cancer prognosis. Oncology 2013;84:219-25.
13. Marx D, Schauer A, Reiche C, et al. C-erbB-2 expression in correlation to other biological parameters of breast cancer. J Cancer Res Clin Oncol 1990;116:15-20.
14. Jarvinen TA, Tanner M, Rantanen V, et al. Amplifiation and deletion of topoisomerase IIa associate with ErbB-2 amplifiation and Affect Sensitivity to Topoisomerase II Inhibitor Doxorubicin in Breast Cancer. Am J Pathol 2000;156:839-47.
15. Slamon DJ, Godolphin W, James CA et al. Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Sci 1989; 244:707-12.
16. Borg A, Baldetorp B, Fernö M, et al. ERBB2 amplifiation in breast cancer with high rate of proliferation. Oncogene 1991;6:137-43.
17. Birner P, Oberhuber G, Stani J. Evaluation of the United States food and drug administration- approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 7:2001:669-75.
18. Eliyatkın N, Özgür H, Erçetin P, ve ark. Meme karsinomlarında HER-2 durumunun immünohistokimyasal ve moleküler analizlerle değerlendirilmesi. Tepecik Eğit ve Araşt Hast Der 2015;25:19-27.
19. Buck A, Schirrmeister H, Kühn T, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic 82 parameters. Euro J of Nucle Med and Molecu Imag 2002;29:1317-23.
20. Petrelli F, Viale G, Cabiddu M, et al. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Ca Res and Treat 2015;153:477-91.
21. Caldarella A, Crocetti E, Paci E. Ki67 in breast cancer: a useful prognostic marker? Ann of Onco 2014;25:542.
22. De Azambuja E, Cardoso F, de Castro Jr G, Colozza M, Mano MS, Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. Brit J of Ca 2007; 96:1504.
23. Railo M, Lundin J, Haglund C, et al. Ki-67, p53, Erreceptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer. Acta Oncolog 1997;3 6:369-74.
24. Inwald E, Klinkhammer-Schalke M, Hofstädter F, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Ca Res and Treat 2013; 139:539-52.
25. Tamaki K, Ishida T, Tamaki N, et al. Analysis of clinically relevant values of Ki-67 labeling index in Japanese breast cancer patients. Breast Ca 2014;3:325-33.
26. Md Paiman N, Ali SAM, MdZin R, Kamal MZM, Amin WAM, Nallusamy M, et al. Estrogen receptor-negative breast ductal carcinoma: clinicopathological features and Mib-1 (Ki-67) proliferative index association. Plos One 2014;9:89-172.
27. Pérez-López M, García-Gómez J, Alves M, et al. Ki-67 is a prognostic marker for hormone receptor positive tumors. Cli and Transla Onco 2016;18:996-1002.
28. Hao S, He Z-X, Yu K-D, et al. New insights into the prognostic value of Ki-67 labeling index in patients with triple-negative breast cancer. Oncotarget 2016;7: 24824.
29. Wiesner FG, Magener A, Fasching PA, et al. Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. The Breast 2009;18:135-41.